Biogen has forged a settlement with investors who claimed the company misled them in describing how it gained a controversial ...

March 31 (Reuters) - Biogen has agreed to acquire Apellis Pharmaceuticals for about $5.6 billion in cash, expanding its ...

Biogen is buying Apellis Pharmaceuticals for $5.6 billion upfront as it looks to expand its immunology business.

Before market open, Biogen divulged in a regulatory filing that it expects to record $34 million in pre-tax expenses in its ...

When a biopharma company known for its expertise in a specific domain turns to a collaborator to expand its capabilities in ...

Biogen’s lupus drug candidate litifilimab has improved outcomes in another phase 2 trial, adding to the momentum behind a program barreling toward pivotal data in two forms of t ...

Biogen said on Monday that it expects Q1 GAAP and non-GAAP net income per diluted share to be impacted by ~$0.19 per share. The charge arises from acquired in-process research and development, upfront ...

In addition to delivering two approved medicines to Biogen’s portfolio, the acquisition of Apellis Pharmaceuticals will ...

March 31, 2026, 2:51 PM ESTHealth Care February 10, 2026, 12:20 PM ESTHealth Care December 01, 2025, 3:48 PM ESTHealth Care July 25, 2025, 7:44 AM ESTHealth Care July 24, 2025, 7:48 AM ESTGovernment & ...

Despite a healthy roster of late-stage assets and a revenue turnaround in 2025, it’s no secret that Biogen has been seeking ...

In an interview, Chief Financial Officer Robin Kramer said the combined cash flow from Biogen and Apellis will not only help ...

By Mariam Sunny and Sahil Pandey March 31 (Reuters) - Biogen will buy Apellis Pharmaceuticals for about $5.6 billion, adding ...